User Name:


remember me

Forgot your password?

Not a member?

Join Now

News Topic - Pfizer

RSS feedDisplaying articles 1 - 10 of most recent articles

Pfizer recalls two lots of migraine drug due to potential bacterial contamination Pfizer Inc. is recalling two lots of its migraine medication Relpax, the U.S. Food and Drug Administration said Thursday. The pharmaceutical company is voluntarily recalling those particular lots because they could potentially be contaminated with two str | Aug 15, 2019 5:26 PM [GMT] | comment? | recommend
GSK's new pharma president carries Merck, Pfizer experience With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.
Triangle Business Journal | Aug 13, 2019 11:27 AM [GMT] | comment? | recommend article from Raleigh, North Carolina
Pfizer's stock sinks again, toward 14-month low to pace 'Dow's' losers Shares of Pfizer Inc. dropped 3.6% in afternoon grading Monday, putting them on track to close at a 14-month low, as the drugmaker extends the rough patch in the wake of its second-quarter earnings report and announcement to merge its Upjohn business with | Aug 12, 2019 5:57 PM [GMT] | comment? | recommend
In-House Pharma Vet Joins Jazz Pharmaceuticals Neena Patil, who held in-house roles at Novo Nordisk and Pfizer Inc., has become general counsel at Jazz Pharmaceuticals Inc. | Aug 7, 2019 7:02 PM [GMT] | comment? | recommend
Photo from WebWire
Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis Pfizer Inc. (NYSE:PFE) announced that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate
WebWire | Aug 7, 2019 6:06 PM [GMT] | comment? | recommend
Photo from Mail Online
Men with erectile dysfunction are twice as likely to be less productive at work A new study from Pfizer, Inc on 52,000 men from 8 countries found that about 25% of men with erectile dysfunction were likely to be less productive at work compared to 11% of men without the condition.
Mail Online | Aug 7, 2019 07:07 AM [GMT] | comment? | recommend
GlycoMimetics stock down 53% after Phase 3 trial failure Shares of GlycoMimetics Inc. fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc. , did not meet primary or secondary endpoints. Shares | Aug 5, 2019 12:56 PM [GMT] | comment? | recommend
Barclays: 3 Reasons to Buy Mylan Post Pfizer Deal Pfizer Inc(PFE)has just revealed a controversial plan to spinoff its Upjohn unit. As a result, Pfizer will lose its portfolio of drugs that are no longer patent-protected including Viagra, Lipitor and Celebrex. Upjohn will merge with rivalMylan NV(MYL), w
Yahoo! News | Aug 4, 2019 2:58 PM [GMT] | comment? | recommend
Best of Lex: your weekly round-up LSE/Refinitiv,, Pfizer, Barclays, StanChart, Altice, Centrica, GAM
Financial Times | Aug 2, 2019 4:27 PM [GMT] | comment? | recommend
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Yahoo! News | Aug 2, 2019 1:54 PM [GMT] | comment? | recommend